The data indicate that autologous DCs, pulsed with the melanoma antigen recognized by T cell 1 (MART-1) peptide, were administered alongside escalating doses of Tremelimumab (an anti-CTLA-4 antibody) to 16 patients with advanced melanoma. The gene discussed is CTLA4; the disease is melanoma.